Finance

Lists
Q3 2026 earnings • 9:00 AM tomorrow
See details
ABBV34:BVMF
Abbvie Inc BDR
R$101.80
0.00%
(0.00) 1D
Oct 29, 5:10:00 PM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for ABBV34...
Open
R$96.74
High
R$101.80
Low
R$96.74
Mkt. cap
513.86B
Avg. vol.
1.27K
Volume
173.00
52-wk high
R$101.80
52-wk low
R$58.29
Shares outstanding
1.77B
No. of employees
57K
Open
R$96.74
High
R$101.80
Low
R$96.74
Mkt. cap
513.86B
Avg. vol.
1.27K
Volume
173.00
52-wk high
R$101.80
52-wk low
R$58.29
Shares outstanding
1.77B
No. of employees
57K
News stories
From web sources and news partners
Profile
AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues. The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'. Wikipedia
About Abbvie Inc BDR
CEORobert A. Michael
Employees57K
FoundedApr 10, 2012
HeadquartersNorth Chicago, Illinois, United States
SectorBiotechnology
Websiteabbvie.com
Next call in 9:11:56
Tomorrow, 9:00 AM
Fiscal period
Q3 2026
- / $3.77
Revenue / Est. (USD)
- / 17.35B
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
15.78B
16.62B
15.00B
16.99B
Cost of goods sold
4.46B
4.55B
4.22B
4.29B
Cost of revenue
4.46B
4.55B
4.22B
4.29B
Research and development expenses
2.29B
2.58B
2.47B
2.34B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.43B
3.82B
3.49B
3.55B
Operating expense
5.72B
6.40B
5.96B
5.90B
Total operating expenses
10.18B
10.95B
10.18B
10.19B
Operating income
5.60B
5.67B
4.82B
6.80B
Other non operating income
199.00M
120.00M
-3.00M
-55.00M
EBT including unusual items
714.00M
2.67B
1.04B
4.28B
EBT excluding unusual items
5.11B
5.12B
4.19B
6.07B
Income tax expense
526.00M
853.00M
342.00M
662.00M
Effective tax rate
73.67%
31.97%
32.92%
15.47%
Other operating expenses
-
-
-
-
Net income
186.00M
1.82B
695.00M
3.61B
Net profit margin
1.18%
10.93%
4.63%
21.27%
Earnings per share
1.86
2.71
2.65
3.65
Interest and investment income
72.00M
59.00M
72.00M
67.00M
Interest expense
-739.00M
-714.00M
-717.00M
-746.00M
Net interest expenses
-667.00M
-655.00M
-645.00M
-679.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
7.66B
7.66B
6.76B
8.68B
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps